# Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia

> **NCT07315373** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Zanubrutinib 80mg/d
- **DRUG:** High dose dexamethasone
- **DRUG:** Zanubrutinib 160mg/d
- **DRUG:** Zanubrutinib 240mg/d

## Key facts

- **NCT ID:** NCT07315373
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-25
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07315373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07315373, "Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07315373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*